Search form

 

Press Releases


Axcan Pharma to present at CIBC World Markets Annual Biotechnology and Speciality Pharmaceuticals Conference in New York City


Apr 21, 2004 - 12:00 ET

Axcan Pharma to present at CIBC World Markets Annual Biotechnology and Speciality
Pharmaceuticals Conference in New York City 

MONT SAINT-HILAIRE, Quebec, April 21 - Axcan Pharma Inc.
("Axcan" or the "Company") today announced that on April 27, 2004,
David W. Mims, Executive Vice-President and Chief Operating Officer of the
Company, will present an overview of the Company's strategy and growth program
at the CIBC World Markets Annual Biotechnology and Speciality Pharmaceuticals
Conference held in New York City. This presentation will take place at
1:45 P.M. EST.

Interested parties can access the audio webcast of the presentation on
the Company's website at www.axcan.com .

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

    "Safe Harbor" statement under the Private Securities Litigation Reform
    ----------------------------------------------------------------------
    Act of 1995.
    ------------

    To the extent any statements made in this release contain information
    that is not historical, these statements are essentially forward looking
    and are subject to risks and uncertainties, including the difficulty of
    predicting FDA approvals, acceptance and demand for new pharmaceutical
    products, the impact of competitive products and pricing, new product
    development and launch, reliance on key strategic alliances, availability
    of raw materials, the regulatory environment, fluctuations in operating
    results and other risks detailed from time to time in the Company's
    filings with the Securities and Exchange Commission.


David W. Mims
Executive Vice President and 
Chief Operating Officer
Axcan Pharma Inc.
(205) 991-8085 ext. 3223; 
Source: Axcan Pharma Inc.